Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary

February 4, 2025

New York Stock Exchange US Health Care Pharmaceuticals earnings 70 min

Earnings Call Speaker Segments

Peter Dannenbaum

executive
#1

Thanks, Shirley, and good morning to all of you. It's a pleasure to welcome everyone to Merck's conference call for the fourth quarter of 2024. Joining us on today's call are Rob Davis, our Chairman and Chief Executive Officer, Caroline Litchfield, our Chief Financial Officer, and Dr. Dean Li, President of Merck Research Labs. Before we begin, I want to note that our GAAP results include items like acquisition-related charges, restructuring costs, and certain other items, all of which we've excluded from our non-GAAP results. A reconciliation can be found in our press release. I'd also like to remind everyone that certain statements we make today may be deemed forward-looking statements under the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These statements reflect Merck management's current beliefs and carry significant risks and uncertainties. Should our underlying assumptions turn out to be inaccurate or should uncertainties materialize, actual results could differ materially from those expressed in the forward-looking statements. Our SEC filings, including item 1A in the 2023 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any forward-looking statements we make this morning. Merck undertakes no obligation to publicly update any forward-looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks; these slides, along with the earnings release, today's prepared remarks, and our SEC filings, are all posted to the Investor Relations section of Merck's website; with that, I'd like to turn the call over to Rob.

Rob Davis

executive
#2

Thanks, Peter. Good morning, everyone, and I appreciate you being on today's call. Across our company, 2024 brought yet another period of major progress, and the steady strides we're taking to create and supply breakthrough vaccines and medicines that help save and improve lives worldwide make me proud. Patients everywhere are feeling our impact. Indeed, during 2024, our medicines and vaccines — donations included — reached close to 0.5 billion individuals. Our attention stays fixed on breakthrough science and innovation as the wellspring of lasting, sustainable value for both patients and shareholders; we keep carrying out our strategic priorities; we keep moving our pipeline forward, introducing vital new products that carry substantial patient benefit and robust commercial promise, pushing ahead with pivotal clinical programs in our strong early and late-phase pipeline, and strengthening that pipeline via encouraging business development. Because of the commitment of our gifted worldwide team, our business stays in a solid position, and my confidence has never been greater in our capacity to move patient care forward while powering Merck's long-term growth potential. Now let's discuss our results and outlook. We posted robust growth in 2024, which mirrors demand for our inventive portfolio — among them Keytruda, which keeps helping more cancer patients globally, the fruitful launch of Winrevair, and the solid showing from our animal health business. Beyond China, we likewise encountered greater demand and recorded robust sales for Gardasil. With 2024 ending and 2025 beginning, conditions in the Gardasil market within China have stayed difficult. As has happened at numerous other firms, pressure has grown on discretionary consumer spending, extending more widely across vaccines as a category, and Gardasil demand hasn't bounced back to the degree we'd anticipated. Consequently, total channel inventory is still sitting high, above typical levels; in view of that, and following additional talks with Zhifei, our commercialization partner, during the last couple of weeks — especially concerning their latest financial disclosure and working capital levels — we've chosen to adopt a fresh approach and halt shipments to China for the time being, starting this month and lasting at least through mid-year. We think acting now will enable a quicker drawdown of inventory and assist in shoring up the financial standing of our significant and appreciated partner. Crucially, we view China as still offering a considerable long-term opening for Gardasil, since so many females — and, with our recent approval, males too — have yet to be immunized, and we stay dedicated and well-positioned to realize that potential over the long haul. Beyond China, Gardasil demand continues to be strong, and we anticipate solid growth both this year and far into the future. Our broader business continues to be quite healthy. In fact, setting aside how Gardasil performs in China, we anticipate the company will produce robust growth in this year's second half, along with 2026 and 2027. When we look further out, nothing has shaken our belief that we can steer through the Keytruda LOE stretch successfully. That view rests on how strong our pipeline is, how enthusiastic we are about the launches of innovative new products already underway and still to come, and the commercial potential those products hold. Now let me move on to what our research teams are doing. Across several therapeutic areas in our late-phase pipeline, the progress has been remarkable. On the fourth quarter call, we noted that the FDA has accepted the submission for clesrovimab — a long-acting monoclonal antibody we developed to protect infants against RSV disease — and we also reported encouraging top-line data from three programs: subcutaneous pembrolizumab, islatravir paired with ibrutinib for HIV treatment, and Winrevair from the ZENITH trial. In addition, we pursued value-enhancing business development, informed by both science and our portfolio. We acquired several promising investigational assets, including a clinical-stage anti-PD-1/VEGF bispecific antibody in oncology from LaNova, and a candidate oral GLP-1 receptor agonist in cardiometabolic from Hansoh. Today, Merck stands on a solid foundation of commercial products that serve important medical needs, and we are moving quickly toward a future in which our portfolio is far more diversified. We have built an expansive pipeline whose potential to push the practice of medicine forward worldwide is tremendous. Expect a steady cadence of data readouts over the months and years ahead, which could lead to new launches as we work to deliver much-needed innovation to patients. In fact, 20 potential new growth drivers sit before us, and nearly all of them carry blockbuster opportunity. This includes Winrevair, along with Capvaxive — the conjugate vaccine for pneumococcal disease in adults that's currently rolling out across the United States — as well as many other novel candidates now in phase 3. Over the past three years, the number of late-stage programs we have has grown to almost three times what it was, covering many different therapeutic areas and modalities. With that kind of advancement, we estimate these programs could bring in more than $50 billion in revenue. By continuing to broaden and strengthen what's in our pipeline, we're set up to lead in oncology over the long term. We see real potential for future expansion in cardiometabolic, and that includes our oral PCSK9 inhibitor program, which has key phase three data coming out this year. In immunology, HIV, and ophthalmology, we have opportunities to advance medicines that could be first-in-class and/or best-in-class blockbusters. On top of that, we expect to gain from encouraging programs in our infectious disease and vaccines pipeline, from solid growth in our animal health business, and from numerous early-phase programs that will advance into phase two across the next few years, and we continue to be well-positioned to seek further science-driven, value-creating business development. In short, my confidence in our long-term future has increased. Even though the Gardasil market in China is shifting quickly and that has become a near-term obstacle for us, the broader business remains sound and expanding. We are still well placed to get through the Keytruda loss-of-exclusivity stretch successfully, while carrying on with our mission of saving and improving lives. Once more, I want to acknowledge how dedicated and hardworking our teams are around the world. Together, we keep our focus squarely on delivering and protecting value for patients, for shareholders, and for all of our stakeholders today and well into the future. With that said, I'll turn it over to Caroline.

Caroline Litchfield

executive
#3

Thank you, Rob, and good morning. As Rob mentioned, we've just wrapped up another year of strong growth, which reflects steady, healthy demand for our innovative portfolio and demonstrates just how important our medicines are to the patients we serve. That growth was driven by oncology, animal health, and the introduction of new products — and those gains were more than enough to offset the difficulties we encountered with Gardasil in China. These results speak to the fundamental strength of our business and give us confidence in our guidance. By executing well commercially and operationally, we can generate value in the near term while continuing to fund new innovations and move our pipeline forward over the long term. Let's now turn to the fourth quarter. Company-wide revenue came in at $15.6 billion, an increase of 7%, or 9% excluding currency movements. Every revenue figure I'll mention from here on is on an exchange basis. Our human health business maintained its momentum, with sales up 8%, driven primarily by oncology. We also saw strong performance in animal health, where sales grew 13%. Now let's review how our key brands did. In oncology, Keytruda sales rose 21% to $7.8 billion, powered by continued robust global demand for metastatic indications and increased use in earlier-stage cancers. Keytruda grew across every major tumor type in the U.S. In metastatic disease, we saw increased uptake of Keytruda in combination with Padcev for first-line locally advanced urothelial cancer, supported by strong results from KEYNOTE-A39, as well as Keytruda plus chemotherapy for first-line endometrial cancer, backed by compelling data from KEYNOTE-868. In earlier stages, growth came from expanded use in resectable non-small cell lung cancer and triple-negative breast cancer. Outside the U.S., growth was driven by higher adoption in earlier-stage cancers, including high-risk early-stage triple-negative breast cancer, along with continued demand in metastatic disease. Inflation-related price increases, consistent with market practice in Argentina, also contributed to growth. Our broader oncology portfolio delivered solid gains, including Welireg, which more than doubled to $160 million, boosted by increased uptake among certain U.S. patients with previously treated advanced renal cell carcinoma. In vaccines, Gardasil sales totaled $1.6 billion, a decline of 18%, reflecting softer demand in China. In the U.S., price and demand supported sales, partially offset by CDC purchasing patterns. In markets outside the U.S. and China, sales grew by double digits, driven by higher overall demand, including the catch-up cohort in Japan. In pneumococcal, Capvaxive generated $50 million, fueled by demand from the retail pharmacy channel; we've made excellent progress toward the commercial milestones required for a successful launch and are well positioned to help protect adults from invasive pneumococcal disease. Vaxneuvance revenue declined by 9%, as gains from launches in international markets were more than offset by competitive headwinds in the U.S. In cardiovascular, we continue to see steady growth from the ongoing Winrevair rollout, which contributed $200 million in sales, primarily in the U.S., where holiday season dynamics somewhat impacted prescription volumes. Approximately 1,500 new U.S. patients received a prescription, bringing the cumulative number of newly prescribed patients to roughly 5,200 since launch. Access remains strong, and what we're observing continues to indicate that about 80% of patients who receive a prescription will ultimately be on commercial product. Importantly, the vast majority of patients remain on treatment. Both the number of prescribing physicians and the depth of their prescribing continue to grow; we're also seeing a rising share of prescriptions written for patients not on prostacyclin background therapy. Outside the U.S., the early launches are progressing well; in short, our confidence in Winrevair's growth outlook remains as we expect to help more people living with pulmonary arterial hypertension. Animal health delivered another quarter of strong growth, with sales rising 13%. Livestock gains were driven by stronger poultry demand, revenue from the Aqua portfolio recently acquired from Elanco, and pricing. Companion animal growth was driven by price. Let me now walk you through the rest of our P&L, and I'll be speaking on a non-GAAP basis. Gross margin was 80.8%, up 3.6 percentage points, due to lower royalty rates on Keytruda and Gardasil plus a favorable product mix. Operating expenses decreased to $7.4 billion. This quarter's charges of $700 million related to the license agreements with LaNova and Hansoh Pharma were lower than last year's $5.5 billion charge for the Daiichi Sankyo collaboration. Excluding those charges, operating expenses increased 10%, which reflects strategic investments supporting our strong early and late-phase pipeline and key growth drivers. Other expense totaled $5 million. Our tax rate was 16.2%. Altogether, earnings per share reached $1.72; turning now to our 2025 non-GAAP guidance; we expect revenue in the range of $64.1 to $65.6 billion, which represents 2% to 4% growth, after excluding an approximate 2% negative foreign exchange impact using mid-January rates. For Gardasil in China, our guidance assumes no additional shipments at the low end and under $1 billion at the high end. Excluding Gardasil sales in China for both 2024 and 2025 along with the FX headwind, total company growth should be 7%-9%. We're assuming a gross margin of roughly 82.5%. Operating expenses are projected at $25.4-$26.4 billion. That range includes a $300 million payment for the LaNova license agreement, which will be recorded once the MK-2010 technology transfer is complete. Keep in mind, our guidance doesn't include any additional significant potential business development deals. Other expense should be between $300-$400 million. We're assuming a full-year tax rate of 16%-17%; we're assuming roughly 2.53 billion shares outstanding. Taken as a whole, we're looking for EPS between $8.88 and $9.03. Inside that guidance is roughly $0.09 related to the LaNova payment we expect, plus an FX headwind of approximately $0.35 based on mid-January rates. A few points to bear in mind as you put your models together. Turning to 2025, we expect to capture benefits from a wider commercial portfolio, with oncology and animal health remaining strong performers, and additional lift from newly launched products. Across the opening half, our revenue projection is roughly flat versus the same period last year, as China-related pressures ought to be offset by high single-digit expansion across the rest of the business. During the second half, we're anticipating a significant year-over-year gain. On Gardasil and the longer view, while we continue to see a path to the $11 billion threshold, we believe stepping back from that target is appropriate given that the timing of a Chinese economic recovery is still uncertain. Our outlook for growth of this important vaccine beyond China is unchanged, and we're well positioned to protect more lives and deliver strong growth beyond 2025. Now for Keytruda: U.S. revenue benefited by roughly $200 million because wholesalers built inventory in the fourth quarter, which we expect to reverse in the first quarter. We estimate Medicare Part D redesign will reduce sales by about $400 million, hitting Winrevair hardest along with our small molecule oncology portfolio, including Welireg, Lynparza, and Lenvima. Early in 2025, we lowered U.S. list prices across the Januvia product family to bring them closer to net prices. That reduced list price will lower the rebates Merck pays to Medicaid, so we expect better net sales for those products in 2025. Switching to capital allocation, our strategy remains the same. Investment in our business comes first to drive near- and long-term growth. We'll continue placing disciplined bets on our core growth drivers and our extensive pipeline. Our dividend commitment is intact, with the goal of consistent increases over time. Business development remains a priority, and we're well positioned to pursue additional science-driven deals that create value. We recently increased our share repurchase authorization by $10 billion to $12 billion in total. Since we have opportunities to invest in the business and bolster the pipeline through business development, we intend to keep buybacks modest this year; we won't allow excess cash to accumulate on the balance sheet, and the bigger authorization gives us flexibility to increase repurchases when appropriate. To wrap up, we enter 2025 encouraged about our business prospects, driven by global demand for our innovative medicines and vaccines, together with our exceptional pipeline. Our commitment that never wavers — bringing the most advanced science to bear so patients' lives improve — has put us in a solid position operationally and on the balance sheet; through putting money into innovation and keeping our eyes on execution, we're positioned to create value for patients, for customers, and for shareholders at present and well into the future. That said, I'll pass things to Dean. This comes alongside $64.1 billion.

Executive

executive
#4

Thank you, Caroline. Good morning, everyone. Progress is being made across several therapeutic areas in both early- and late-stage programs. In my remarks today, I'll walk through the key developments since our previous earnings call and give a rundown of 2024's highlights. To begin with cardiometabolic disease: the phase III ZENITH trial, which assessed Winrevair in pulmonary arterial hypertension patients considered at high risk, showed a statistically significant decrease in the risk of morbidity or mortality events versus placebo, in both cases on top of background PAH therapy. Given that efficacy was so compelling, the study was halted so that every participant can choose to receive Winrevair. The complete findings will be presented in late March at ACC25, the American College of Cardiology's conference. Merck and the external steering committee unanimously decided that the Phase III HYPERION trial should be halted ahead of schedule after reviewing all efficacy data from the Winrevair clinical program, which included favorable Zenith results. The FDA has been consulted on this matter, and study investigators have been notified. Given the compelling clinical benefit demonstrated by Winrevair in the STELLAR and Zenith trials, it was concluded that clinical equipoise no longer existed for the Hyperion study. Blinding will be maintained, and all participants may opt to obtain Winrevair via the open-label long-term extension study known as SoterIA. Later this year, we anticipate that data will become available, and at a future medical congress, we will present it. This highlights a growing acknowledgment that Winrevair — the first and only activin signaling inhibitor approved for treating PAH — might change how medicine is practiced and could be transformational for patients who live with this progressive and debilitating disease. Globally, Winrevair has been approved in over 35 countries. An application for approval was recently submitted by us to regulatory authorities in Japan. Turning to the broader cardiometabolic area, in December we entered into a licensing agreement with Hansoh Pharma that covers an investigational preclinical oral small molecule GLP-1 receptor agonist, now referred to as MK-4082, which is set to enter the clinic this year. Our deep background in incretin biology means we're in a strong spot to push forward oral small molecule combinations that include a GLP-1 agonist, pairing them with next-gen weight loss treatments and others aimed at cardiometabolic disease. Moving on to infectious diseases. For clesrovimab — our long-acting monoclonal antibody given prophylactically to infants heading into their first RSV season, the period when severe illness poses the biggest threat — the FDA has assigned a target action date of June 10. Should it win approval, clesrovimab would become the first and only single-dose passive immunization for infants no matter what they weigh, potentially shielding babies throughout the entire RSV season. Now for our HIV update: we shared top-line data from a pair of pivotal phase III studies. Those trials looked at an investigational oral combo taken once a day — doravirine plus islatravir — in adults living with HIV whose virus was already suppressed while on other antiretroviral regimens. We'll present the detailed results at a scientific congress later on, and we intend to file the data as part of a regulatory submission package. Islatravir works as a nucleoside reverse transcriptase translocation inhibitor and has the potential to be first-in-class; it's also being evaluated in multiple late-stage trials in combination with other antiretroviral agents for treating HIV. We're also testing it in active phase III trials alongside lenacapavir, Gilead's capsid inhibitor, as a once-a-week pill option. In addition, MK-8527 — another NRTTI candidate still under investigation — is being explored as a potentially important once-a-month oral alternative for pre-exposure prophylaxis, and we expect to advance it into phase III within this year. Turning to vaccines: Gardasil has received approval from China's National Medical Products Administration for preventing certain HPV-related cancers and diseases in males aged nine to 26. In November, during the International Papillomavirus Conference, we shared new clinical and real-world data on Gardasil 9 looking at oral HPV infection prevalence, the burden of HPV-related head and neck cancers, and HPV infection rates among females; this evidence strengthens the case for gender-neutral HPV vaccination using Gardasil in adults through age 45. More recently, the American Cancer Society's yearly report on cancer facts and trends pointed to a rise in cervical cancer diagnosis rates among females ages 30 to 44. There's still a need to protect more people from HPV-related cancers. In Europe, the European Medicines Agency's Committee for Medicinal Products for Human Use backed approval of Capvaxive for active immunization to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae in adults. Turning to oncology, our phase III trial assessing the investigational subcutaneous fixed-dose combination of pembrolizumab and hyaluronidase alfa plus chemotherapy versus intravenous Keytruda plus chemotherapy achieved its dual primary pharmacokinetic parameter endpoints of non-inferiority. Should it be approved, this administration route would offer a meaningful option for patients. We intend to share detailed study findings at a scientific congress soon. Our oncology pipeline is growing and becoming more diverse, and that showed at the American Society of Hematology annual meeting, where more than 20 abstracts were presented from studies looking at treatment options for various hematologic malignancies. Among those was early data from the phase II WAVELINE-007 trial of zilovertamab vedotin, an investigational antibody-drug conjugate targeting ROR1, in diffuse large B-cell lymphoma patients. When it comes to regulatory matters, we secured three approvals in China for regimens based on Keytruda. These include a neoadjuvant adjuvant regimen for resectable non-small cell lung cancer patients, supported by KEYNOTE-671; treatment for certain locally advanced cervical cancer types, supported by KEYNOTE-A18; and first-line treatment for urothelial carcinoma patients in combination with Padcev, supported by KEYNOTE-A39. On top of that, Welireg got the green light to treat adults who have VHL-associated renal cell carcinoma, and that decision rested on LITESPARK-004. Over in Japan, the Ministry of Health, Labour and Welfare signed off on two regimens built around Keytruda — one of them being therapy for advanced cervical cancer based on KEYNOTE-A18, and the other for primary advanced or recurrent endometrial carcinoma based on KEYNOTE-868. Turning to the United States, the FDA has handed breakthrough therapy designation to Sac-TMT, which is our investigational TROP2-directed antibody drug conjugate, for use in certain patients whose advanced non-small cell lung cancer has already been treated before. We're advancing this program through a collaboration with Kelun-Biotech, and at present 10 phase III studies are running across a variety of solid tumors. Then, in December, we closed an exclusive global licensing deal with LaNova Medicines covering a novel investigational PD-1/VEGF bispecific antibody, which we now call MK-2010. Our intention is to examine the fullest potential of MK-2010 across a variety of tumor types within a worldwide patient population. Like Rob said, 2024 stood out for meaningful advances in the pipeline. Over 20 phase III trials got underway, covering cardiometabolic, immunology, infectious diseases, oncology, ophthalmology, and vaccines. We secured more than 25 regulatory approvals across major regions, among them Winrevair and Capvaxive. At the same time, we made good on our one-pipeline approach, using what we know clinically and our dealmaking capabilities to identify and secure external assets where science, unmet medical need, and value intersected — the goal being to expand, complete, and add greater variety to our pipeline. Our acquisitions of Harpoon Therapeutics and EyeBio, along with an asset acquired from Curon Biopharmaceutical, delivered important new biologic candidates across oncology, ophthalmology, and immunology, in that sequence. And via licensing deals with Hansoh Pharma and LaNova Medicines, we secured rights to candidates with significant potential in cardiometabolic disease and oncology. Important events on the horizon for 2025 include comprehensive data from the ZENITH study, covering islatravir-containing HIV treatments and subcutaneous pembrolizumab in oncology, as well as Keytruda for head and neck squamous cell carcinoma at an earlier stage — every one of these will be shared at future medical congresses. Additionally, we anticipate readouts from three phase III registration-enabling trials involving MK-0616, our oral PCSK9 inhibitor candidate, aimed at hypercholesterolemia; and the primary completion for the phase II CADENCE trial of Winrevair in pulmonary hypertension stemming from left heart disease is scheduled this autumn. I look forward to providing further news about the advances in our pipeline. With that, I'll return the call to Peter.

Peter Dannenbaum

executive
#5

Appreciate that, Dean. Shirley, let's open it up for questions now. I'd ask that the analysts keep it to a single question each so we can fit in as many people as possible. Thanks. Thanks.

Umer Raffat

executive
#6

Good morning, everyone. I appreciate you taking my question. I understand there are many people talking about Gardasil today, but let me turn to a different growth driver that came in a bit below consensus: Winrevair. What I'd like to know is, when we consider how growth will unfold as we move through 2025, some claims data has raised doubts that the beginning of the year may have come in somewhat softer than certain growth expectations. So would you say you're reasonably confident that Winrevair can achieve roughly 100% growth year over year from the fourth quarter of this year through the close of 2025? Thank you.

Rob Davis

executive
#7

Yes, Umer, I appreciate the question. Rob here. I'd simply put it this way: on the whole, nothing has shifted regarding how confident we are in Winrevair, the possible advantages it offers to individuals dealing with PAH, and consequently how vital it is to our expansion. When we examine what's taking place in January, in fact, we're observing January coming back to the figures we'd have anticipated. When we turn to 2025, we genuinely regard this as a significant driver of growth, and every one of the basics we're seeing backs that up. Great.

Peter Dannenbaum

executive
#8

Next question, please, Shirley.

Terence Flynn

analyst
#9

Hello there, and good morning. I appreciate you taking my question. I was simply curious whether the shift in Gardasil sales for the outer year has any bearing on how you view the scale, the nature, or the timing of your M&A and business development approach at this point. Might this create an opportunity for bigger deals now? Thank you.

Rob Davis

executive
#10

Right, thanks for asking that. Looking ahead — and I believe we've, well, stayed quite steady on this — the expectations we held for the long haul at this company, particularly once we enter the LOE period, never involved relying on Gardasil as something to drive growth, since we always figured that at some point it would level off once we'd moved through every cohort and were essentially back to the birth cohort alone. So going forward, what we expect the period after LOE to look like is, honestly, no different from what I said before; that being said, as we've also shared, though I feel, you know, more and more sure about that stretch, we've consistently stated our belief that more needs to be done to keep strengthening the pipeline we've assembled. And so, we'll keep pushing on business development, and we're examining it across a complete spectrum, with science always as the primary consideration. Yet if value is there, along with a connection to our strategy where science intersects, we'd be ready to act, and it will remain in that, you know, $0-$15 billion range, which is our sweet spot, though clearly we're open to considering deals; and as we've likewise mentioned, commercialized assets are fair game too if they match the overall profile I described concerning science and value. Great.

Peter Dannenbaum

executive
#11

Thanks, Terrence. Next question, please.

Luisa Hector

analyst
#12

Oh, hello there. Thanks for letting me ask. Maybe regarding the oral PCSK9, might you give us a little additional detail on the cholesterol reduction you're aiming for, and would we possibly have to wait for all 3 studies to report before a press release comes out? Also, I believe earlier you brought up possible combos. Clearly, you now have optionality with the oral GLP, so maybe a bit of detail on where further development might take you. Thank you.

Analyst

analyst
#13

I'll handle that one. Many thanks for those questions. Dean here. Yes, so we've got 3 phase III studies currently running, which ought to produce results in April, July, and August of 2025. My guess is that there's a chance, assuming a major conference happens late in the year, that we'd be hoping to share that data in a public setting; as for our goal with the oral PCSK9, I'd simply point to what the antibodies are capable of and say our aim is a highly comparable profile to the PCSK9 antibodies, but in a pill form, since we see a significant unmet need. You know, 70% of patients taking statins haven't reached goal, so we view this as a potentially important body of data, and should results be positive, we're keen to bring this to the broader population, not only across the United States but worldwide. When it comes to combinations, several are possible, and I appreciate how you phrased it, because ultimately this matters greatly as a standalone drug, yet it also serves as a platform for adding other key cardiometabolic assets, or compounds that might deliver even better cardiovascular outcomes. And so, you know, we'll likely share that data somewhat later, once we've gotten the phase IIIs cleared for the oral PCSK9 inhibitor, MK-0616.

Peter Dannenbaum

executive
#14

Great. Thanks, Louisa. Next question, please.

Mohit Bansal

analyst
#15

Excellent. I really appreciate you taking my question. I apologize for joining somewhat behind schedule, but regarding the question, have you said anything about the amount of inventory that Zhifei currently holds for Gardasil? Would the choice to halt shipments, meaning positive shipments, during the first half address that inventory? I'm simply attempting to grasp the demand circumstances in China too. Thank you.

Rob Davis

executive
#16

Okay, Mohit, I appreciate that question. We haven't given any specific figures regarding the amount of inventory Zhifei is holding. Since they are a publicly traded entity, it's up to them to decide what they want to say about it. What matters most here, though, is recognizing that based on what we're seeing in the market, our goal is to speed up that reduction. So we plan to ship — and honestly, by skipping shipments in February, possibly through the middle of the year and maybe beyond that, depending on how the inventory comes down — we're going to let the demand that remains absorb the JFA inventory and strengthen JFA's financial position and working capital. We believe that if we can move past this inventory issue, we can return to a more typical market environment, one where demand combined with the upcoming male indication can bring us back to growth. As for how quickly we deplete it, we'll have to wait and see. But another thing I'd point out for context regarding this rebasing: Gardasil China now represents roughly 1% of our overall earnings. It's also becoming 1% of total revenue. So that's clearly something important to grasp, and it's why we also emphasized that as the business moves through the latter part of this year and we lap the Gardasil China situation, we'll see strong growth — for Merck overall too — as we head into 2026 and 2027. That matters because at that stage, anything happening with Gardasil in China becomes upside; and that's really the reason we chose to rebase this now, recognizing it's a shift from the approach we'd previously followed.

Peter Dannenbaum

executive
#17

Excellent. Appreciate it, Mohit. Let's take the following question.

Daina Graybosch

analyst
#18

Hello, and thank you for taking my question. I'd like to pose one more regarding Winrevair and the HYPERION trial. Could you give us some clarity on which results you might be in a position to deliver from that study, considering the enrollment and the follow-up? Might you be able to speak to the primary endpoint, or to any of the trends that in your view would back its use among these patients with less severe disease, a group where I believe doctors have greater concern about toxicity risk? Thank you.

Analyst

analyst
#19

Thanks for asking that. Let me pull back for a second, and then I'll address your HYPERION point directly. When it comes to Winrevair, we set out to bring forward a first-in-class way of working — one that inhibits activin signaling. This molecule was engineered to hit the root genetic cause in humans. Our effort is about building a solid wall of evidence proving that this new mechanism is able to shift how medicine is practiced. As for STELLAR, it has already secured both FDA clearance and approval worldwide, and it plainly raises exercise capacity, betters functional class, and reduces the likelihood of clinical worsening. ZENITH carries huge weight, since in my view it's the first PAH study ever run against hard outcomes. I'd add that this marks what I understand to be the first PAH study ever stopped ahead of schedule because the efficacy was so compelling. My guess is that when 2025 ACC comes around, attendees will fix their attention on those results, scrutinizing lung transplantation, hospitalization, and death, and they'll also want to know how quickly those gains appear following treatment. That leads me to HYPERION, whose enrolled patients closely resemble those in STELLAR. Here Winrevair is given earlier in the course of care for that same kind of patient, and a choice was taken to end the study prematurely. The trial is still blinded, yet after reviewing the full body of data, the investigators genuinely concluded that keeping patients on treatment could not be justified on ethical grounds. We'll need to wait and see what those results show, since the study is still blinded. With any luck, we'll get that information along with additional news. Once again, though, the ZENITH findings are going to be presented at ACC. We keep gathering safety information from the phase III readouts and from patients who subsequently moved into SOTERIA. Our long-term safety record sits very comfortably inside what the label allows. As a reminder to everybody, the label specifies 4% for the treated group versus 1% for placebo — so roughly a 3% difference. We remain well below those thresholds. As additional data comes in, it will reach the public more and more during this year, as our investigators prepare presentations and publications. Our goal of transforming how pH is treated is gaining more and more backing. As far as I'm aware, there isn't another activin signaling inhibitor being tested in clinical trials. On top of that, we're obviously looking into additional types of pulmonary hypertension beyond pH.

Peter Dannenbaum

executive
#20

Thanks, Dana. Let's take the next question, Shirley.

Geoff Meacham

analyst
#21

Appreciate you fielding that. I apologize for keeping on about Gardasil, but considering how things stand in China, you folks seem more hesitant to give a timeline for when it will bounce back. Still, my question, Rob, is this: is there some inventory level that has to be reached before you'd begin moving things again? I wasn't clear on what sort of threshold would trigger that. And on a wider note, with the political environment around vaccines being what it is, perhaps you could say where this TA sits within your BD or internal R&D priorities, and whether that's shifted at all. Thanks so much.

Rob Davis

executive
#22

Yes. Joe, I appreciate your remarks. Regarding China specifically, there isn't a particular inventory figure I'm willing to lock in on. Clearly, it has to decline substantially from its current point. By halting shipments, since demand exists, I believe we'll witness that occur. We simply must allow the process to play out, as that economy remains weak, which explains why customer demand keeps being soft. As things get resolved, that will, in my view, set how quickly all this unfolds. Still, it matters to stress once more that by resetting this now, this represents upside. It isn't central to our future growth narrative. That's another thing we need people to grasp. I know this is a substantial shift, and we intend to do, and will do, whatever it takes. We remain strongly dedicated and well positioned to generate growth in China. Yet for me right now, that will be upside for the business; past that, the range of what we offer will fuel expansion in oncology, in animal health, and through our new launches. Turning to vaccines overall, we still regard that field as a key one. Naturally, Capvaxive is there, and it's launching right now. Clesrovimab, a monoclonal antibody targeting RSV, is something we're hoping to secure approval for and see arrive ahead of this year's RSV season. We also have additional programs in development, with Dengue likely being the most notable among the others. So our attention stays there. I wouldn't describe vaccines as a major pillar of our BD approach, mainly since we simply haven't encountered many chances in that area. Even so, we remain dedicated to advancing the R&D efforts we're conducting there going forward and still think there's potential in it. Great.

Peter Dannenbaum

executive
#23

Thank you, Jeff. Next question, please, Shirley.

Chris Schott

analyst
#24

Thanks a lot. I have one more question about Gardasil. On the long-term guidance, I fully understand that near-term dynamics call for an inventory reduction, but now that the $11 billion target has been removed, how much of that, I suppose, is conservatism because of what's going on in China versus a more permanent reset in how you see the Chinese market? I'm just trying to understand it. And as part of your answer, maybe you could talk about Gardasil ex-China. Has anything changed in your longer-term view of the global opportunity for the product outside China? Thank you.

Rob Davis

executive
#25

Yeah. No, thanks for the question, Chris. Okay, regarding China—like Caroline mentioned earlier—we continue to think there's a route to that $11 billion figure. Even so, pulling the target right now makes sense, since we can't be sure about when things will bounce back there or how big the rebound will be. Still, if you dig into the fundamentals that originally gave us confidence about growth in China, those haven't gone away. There remain over 100 million women—120 million women—across tier one to five cities who haven't gotten vaccinated yet. Then there's the male indication, where we were the sole company holding it, and that launch is happening right now. Clearly, that group is roughly equal in size to the female population—around 200 million when you consider the full potential, once we enter that market. So the chance is definitely there; what we have to work through are the immediate inventory situation and the current economic conditions; that's the reason, you know, I believe it makes sense to simply state that we need to wait until we observe that, since China accounted for a significant portion of the $11 billion. That is why we chose to say, let's scale back on the $11 billion. When we examine all the other global markets, our perspective on revenue for the rest of the world hasn't shifted. Caroline mentioned this too — setting aside Gardasil China, we achieved another year of robust double-digit expansion internationally. Looking ahead, outside of China, we anticipate solid year-over-year increases for Gardasil annually. So our long-term outlook stays the same. We still need to resolve what's happening in China, get past this market dynamic, and determine the real growth and opportunity there. Before we get there, I'd like to take that topic off the table. Dwelling on it repeatedly makes us overlook the considerable assets elsewhere—our robust pipeline and our business's expanding scope—which form the true bedrock of the long-term expansion we've delivered and will keep delivering. I want everybody focused on that, because that's exactly where our focus sits.

Peter Dannenbaum

executive
#26

Appreciate it, Chris. Let's take the following question.

Tim Anderson

analyst
#27

Thanks. I've got a few things to ask regarding KEYTRUDA. Over the past six months, I doubt Gardasil's effect on the stock would have been this significant without those deeper worries surrounding Keytruda's entry into the IRA during 2028 and its patent expiration at 2028's close. First, when do you think Merck might be ready to discuss forward-looking guidance covering a longer horizon, similar to what many other businesses do for this stretch of time? Right now, the message is that you can get through this period successfully, yet no numbers are provided. In my view, that quantification is necessary. Then my second question concerns Keytruda in the nearer term. Two competitor readouts in 2025 that go head-to-head against Keytruda have investors concerned. Astra's AVANZAR trial involving the TROP2 is the first. Summit's data involving the PD-1/VEGF is the second. It would be helpful to hear Dean's thoughts on both of those readouts. What do you consider a realistic worst-case scenario? Thanks.

Rob Davis

executive
#28

Yeah. Tim, I appreciate the question; and, as you mentioned, I understand the attention is on the post-LOE situation. We've attempted to provide some direction. If you recall our comments at JPMorgan, we laid out fairly clearly our view; namely, consider how business development combines with progress in our pipeline spanning oncology, and none of this involves Keytruda at all. That means small molecules, the individualized neoantigen therapy, and our ADC portfolio, along with ophthalmology, plus what we're seeing in HIV and cardiometabolic — you can review that entire list. We identified more than $50 billion in what we regard as potential. That's the reason we keep describing a hill rather than a cliff, and my belief in that growth trajectory we presented remains intact. Whether and when we provide long-term guidance is still undecided. It always cuts both ways, so we ought to be careful about it. Still, I understand that as time passes, we must keep offering proof points such as what Capvaxive is showing, what Winrevair is showing, and what we're sure you'll see once MK-0616 and its data begin to emerge, along with other products in development. Over time, those proof points will build confidence. That said, I take your point on guidance, and we'll give it thought, though at present we have no plan to do so.

Analyst

analyst
#29

Yes, this is Dean. I'll respond only regarding that Daiichi Sankyo TROP2 ADC you brought up. Our TROP2 program is something we feel quite good about. As you may be aware, we currently have 10 phase III trials underway. We're really looking forward to seeing those advance, and our confidence there is strong. As for the VEGF PD-1 you mentioned, I'd simply note that we and other companies have studied PD-1 plus VEGF combinations extensively on their own, including alongside Keytruda. The widespread view is that while there are numerous instances of better progression-free survival, those gains haven't shown a consistent pattern of translating into OS. Important research from others, I believe, points to possibly greater PFS for PD-1 or PD-L1 with VEGF, yet that still has to prove OS. Our perspective, though, is that Merck holds a unique position to investigate this, and is a company with an edge that could genuinely determine whether VEGF PD-1 delivers an OS benefit. Should it do so, our infrastructure—spanning 41 indications and 18 tumor types, with nine in earlier stages and four having OS—means we can swiftly deliver this innovation to numerous patients and numerous cancers if it indeed produces OS. Great.

Peter Dannenbaum

executive
#30

Thank you, Tim. Next question, please.

Akash Tewari

analyst
#31

Thanks a lot, and sort of extending what was just discussed — your group just raised its fresh product forecast in oncology, moving it from $20 billion up to $25 billion, even after the setbacks we've witnessed involving TIGIT as well as LAG-3. What roughly are the pieces that make up that $25 billion number, especially regarding TROP2 and the Daiichi ADCs? And Dean, in what ways do you see your TROP2 approach as different from Astra's with Dato-DXd? Do you see specific biomarker groups where Merck comes out ahead in both first- and second-line lung? Thank you.

Rob Davis

executive
#32

Thanks, Akash, appreciate that. When you examine what constitutes the $25 billion, let me be clear — the IO-IO combos were never included in it. They were always additive to it. That $25 billion consisted of our antibody-drug conjugate efforts, from Kelun as well as Daiichi Sankyo, plus a collection of small molecule transactions we completed, mainly in targeted molecular methods against cancer. That covers, so to speak, LSD1, CYP11A1, that whole set of programs, the INT, meaning the individualized neoantigen therapy, and our collaboration with Moderna. Those are what formed the number. Two factors shifted things and gave us greater confidence. First, we brought in the T-cell engager from Harpoon, which excites us a lot, on its own and possibly combined when we consider small cell lung cancer. And above all, our TROP2 effort, we believe, will end up doing better than we first anticipated as we keep watching the data come through. So we're quite positive on that $25-plus billion figure. Beyond that, and this matters, we remain highly confident in subQ Keytruda, which, as we mentioned at JPMorgan, will — you'll see data readouts. It gets filed this year, and ideally could even launch before this year ends. That's another thing we stay very confident about; it isn't counted inside that $25-plus billion. That point matters. Across oncology overall, once you account for everything we'll have, we'll be far bigger than that.

Analyst

analyst
#33

Yes. So I’ll respond as fast as I can. One point where I’d exercise a bit of caution is whenever people discuss TROP2 or HER2 ADCs as though every molecule were identical. These molecules differ substantially. We’ve already observed that with Kadcyla in HER2, and the same holds true when you consider ADCs directed at the same kind of target. So our confidence in the design of Sac-TMT is high. But also, from the start, something we’ve consistently emphasized is that reaching the correct patient population matters. Chemo plus pembro has a broad effect. And in each trial we conduct, we ask ourselves which patient population a Sac-TMT or any ADC would be set apart from that baseline. Regarding the other Daiichi Sankyo assets, patritumab, you know, our interest is strong in relation to breast. For B7H3, our interest is strong in small cell lung cancer. For CDH6, our interest is strong in ovarian. And our interest is strong in pairing and switching some of them with T-cell engagers. I do want to highlight one thing, regarding the design of the Kelun as well as the Daiichi Sankyo. You know, those are truly, I think, important molecules, and we believe that if we reach the correct patient population and pair them with the right IO strategy, whether that’s T-cell engagers or PD1s, we will deliver differentiated profiles for patients.

Peter Dannenbaum

executive
#34

Thank you, Akash. Next question, please.

Trung Huynh

analyst
#35

Hello, everyone. I appreciate you taking the question. I'd like to inquire about the tariff developments that came to light over the weekend. Could you discuss the manufacturing presence your company has in China, Mexico, and Canada? Additionally, the administration has brought up some points regarding transfer pricing. Since Keytruda's IP is situated in Ireland, what kind of effect might that have on Merck if transfer pricing becomes a target as well? Thanks.

Caroline Litchfield

executive
#36

Thanks for asking, Chong. Our organization, in common with numerous others, maintains a manufacturing presence that supports worldwide supply; the amount of production we carry out in China, Mexico, and Canada is quite minimal. For the tariffs proposed over the weekend affecting those nations, we would anticipate an extremely negligible effect. We'll keep evaluating the circumstances in light of the various tariffs being put forward by the U.S. government, yet we stay confident about our supply chain and our capacity to provide our medicines and vaccines globally. Great.

Peter Dannenbaum

executive
#37

Thanks, Chong. Let's take the next question.

Vamil Divan

analyst
#38

Thanks for fielding this. Perhaps if we circle back to Winrevair — clearly there's encouraging data from Zenith and Hyperion. I'm wondering whether that shifts anything about how you view Cadence. My sense is that's a potentially undervalued catalyst coming later in the year, and it's a distinct indication. But, Dean, I'd like to know whether there are any takeaways we ought to draw from the momentum you're seeing there. And relatedly, could you say something about whether inventory movements of any kind — which I believe affected the sales figure across the first couple of quarters — played a role? I just want clarity on whether that was a factor for Winrevair in the quarter just reported.

Akash Tewari

analyst
#39

Sure. Let me address the Wynrivar matter as it relates to the various patient groups. Someone with pulmonary hypertension may have it as a consequence of PAH. My level of conviction that Winrevair could help reshape the standard of care and the treatment paradigm for PAH is extremely strong, particularly given that this molecule was designed around the genetic basis of the disease. We're examining broader implications, since pulmonary hypertension can arise through pathways other than PAH, and we're quite keen to learn how it performs in a heart failure population, so those results remain to be seen. The preclinical data, you know, indicate that this is a meaningful experiment for us to conduct, and we're keen to advance it, and we look forward to the findings.

Caroline Litchfield

executive
#40

Regarding inventory for Winrevair, nothing out of the ordinary has come up. Levels of inventory were typical when we closed out the year. During the quarter, we did incorporate an adjustment tied to the value of inventory sitting in the channel, reflecting the Medicare Part D redesign .

Peter Dannenbaum

executive
#41

Excellent. Appreciate it, Vamil. Let's take the following question.

Courtney Breen

analyst
#42

Hello there. Courtney here. Thank you for taking my call. I apologize — I was just getting off mute. There are two points I hoped to clear up. First, circling back to Gardasil, and I realize this topic has drawn plenty of discussion. Could you give us some detail on whether any write-off exposure exists when we consider the inventory held in Zhifei's channel and how old that inventory is? Then my second point concerns the part D redesign. I realize you just referenced that specifically in connection with Winrevair and the channel dynamics involved there. But when you look at 2025 and a few of the guidance figures peer companies are starting to put out, and we've observed varying ranges and varying readings, could you offer us some context on what you've assumed regarding volume versus price as we consider that $400 million guidance?

Caroline Litchfield

executive
#43

Appreciate that, Courtney. When it comes to Gardasil stock, as Rob mentioned, we're pushing shipments out so that Zhifei can move that product in the market, and that stock belongs to our partner. Because of that, the chance Merck takes a write-off on it is very small. Turning to the Part D redesign, there are two forces at play. The first one is the effect on price, and as we said in our prepared remarks, that hits mainly Winrevair and our oral oncology medicines. We expect that to be partly offset by some volume gain from patients remaining on treatment, but the bulk of the $400 million we mentioned is really the price effect.

Peter Dannenbaum

executive
#44

Great. Thanks, Courtney. We have time for one final question, please. Shirley, thank you.

James Shin

analyst
#45

Hi there, good morning, everyone. Are you able to hear me? Yes. Yeah. Great. My apologies for that. I was only verifying that the technical debugging was working. I don't want to spend too much time on the Gardasil subject, but a meeting of ACIP is coming up in February 2025, and based on the agenda, it appears there will be some follow-up regarding the dosing questions from last October. Could you help set our expectations for that February session? Also, when it comes to the long-term guidance for Gardasil, did the U.S. market have any part in that revision to guidance, or in the guidance being withdrawn? Thank you.

Tim Anderson

analyst
#46

Yeah. Perhaps I'll handle the latter portion of that question, and Dean can address the earlier portion. No, nothing has changed. So, like we mentioned before, with China taken out, what we anticipate for the remaining regions, the U.S. included, stays the same. So our long-term confidence in Gardasil hasn't shifted on that front. When it comes to ACIP and the dosing issue, we'll simply have to wait and find out where things land. You know, we still hold the view that the clinical data's strength backs the two and three-dose regimen that exists today. That's quite a demanding threshold, and I'll let Dean perhaps weigh in on what the FDA and other viewpoints have to say. But, you know, I believe we need to observe how this develops. Yet we remain firmly of the opinion that the dosing is suitable and don't really view that as a risk here in the U.S. But I'll let Dean weigh in.

Dean Li

executive
#47

Yeah; so, the way I'd frame it, ACIP falls under CDC. The label belongs to FDA. Dose scheduling is the FDA's domain. And I'd simply note that Gardasil's dosing schedule has undergone rigorous scrutiny from the FDA. As you've observed, as we moved from three doses to two doses, the evidentiary proof that the FDA demands in order to alter scheduling is substantial. I should also stress that we've held discussions with the FDA regarding how we might design and achieve a randomized control trial capable of changing schedules for Gardasil, Gardasil 9 among men and among women. The FDA, as you can picture, maintains a very demanding threshold for such proof. Now, I'd guess that the outstanding track record of efficacy and safety shapes the FDA's, you know, elevated standards and rigorous standards for anybody wanting to modify the label. I can't say what's going to happen, but I might suspect, particularly at this point, that the FDA's deep focus and expertise regarding dosing and scheduling could matter to the CDC as they determine how they determine this matter of establishing a schedule that sits outside the FDA's label.

Peter Dannenbaum

executive
#48

Great. Thanks, Dean. Thanks, James. Rob, a couple of comments to close the call?

Rob Davis

executive
#49

Yes. Well, I appreciate everyone taking the time to join us. You know, perhaps as a way to wrap things up, I simply want to reaffirm how confident we are over the long haul. I understand that what's happening with Gardasil in China represents a shift. I believe the choice we're making at this point—to move past this, clear up the inventory issue, and keep going—is the correct one. But, you know, setting that to one side, it's a near-term matter. If you place it within the bigger picture of where this company is headed over time. As we've mentioned, we anticipate robust expansion during the back half of the year, carrying us into 2026, and then into 2027. And crucially, when we consider what comes after that, the power of the pipeline, the breadth of the pipeline, the advancement of the pipeline is remarkable; and I truly believe that once we have a complete grasp of all of it—and I acknowledge that proving it will require milestones over time—you'll see why our long-term confidence is what it is. And we're dedicated to showing that and, above all, to keep pushing that pipeline forward for the patients we serve. So, with that, I'll bring the call to a close. Thank you.

Operator

operator
#50

Thanks. That brings today's call to a close, and we appreciate everyone taking part. You're now free to hang up.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.